Text Size

An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients

This study has been terminated.
(The study was stopped due to low enrollment.)
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00127101
First received: August 2, 2005
Last updated: April 7, 2010
Last verified: April 2010
History of Changes
Results First Received: July 6, 2009  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Pharmacokinetics/Dynamics Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Lymphoma
Interventions: Drug: vorinostat
Drug: Comparator: bexarotene

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Cohort 1 Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter[2] daily x 7 days per week
Cohort 2 Vorinostat 300 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter[2] daily x 7 days per week
Cohort 2a Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 225 milligrams/meter[2] daily x 7 days per week
Cohort 2b Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 300 milligrams/meter[2] daily x 7 days per week
Cohort 6 Vorinostat 400 milligrams daily for 7 days per week + Bexarotene 150 milligrams daily for 7 days per week
Cohort 7 Vorinostat 400 milligrams daily for 7 days per week + Bexarotene daily for 7 days per week [150 milligrams (Cycle 1) 225 milligrams (Cycle 2-6)]

Participant Flow for 2 periods

 Period 1:   Base Protocol
    Cohort 1     Cohort 2     Cohort 2a     Cohort 2b     Cohort 6     Cohort 7  
STARTED     3     5     3     3     5     4  
COMPLETED     1     1     1     3     3     3  
NOT COMPLETED     2     4     2     0     2     1  
Adverse Event                 0                 2                 1                 0                 0                 0  
Lack of Efficacy                 1                 0                 0                 0                 2                 0  
Withdrawal by Subject                 1                 2                 1                 0                 0                 1  

Period 2:   Continuation Phase
    Cohort 1     Cohort 2     Cohort 2a     Cohort 2b     Cohort 6     Cohort 7  
STARTED     0     0     1     0 [1]   3     3  
COMPLETED     0     0     0     0     0     0  
NOT COMPLETED     0     0     1     0     3     3  
Adverse Event                 0                 0                 0                 0                 1                 1  
Lack of Efficacy                 0                 0                 0                 0                 0                 1  
Withdrawal by Subject                 0                 0                 1                 0                 2                 1  
[1] No patients from the 2b Cohort entered into the extension phase



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Cohort 1 Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter[2] daily x 7 days per week
Cohort 2 Vorinostat 300 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter[2] daily x 7 days per week
Cohort 2a Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 225 milligrams/meter[2] daily x 7 days per week
Cohort 2b Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 300 milligrams/meter[2] daily x 7 days per week
Cohort 6 Vorinostat 400 milligrams daily for 7 days per week + Bexarotene 150 milligrams daily for 7 days per week
Cohort 7 Vorinostat 400 milligrams daily for 7 days per week + Bexarotene daily for 7 days per week [150 milligrams (Cycle 1) 225 milligrams (Cycle 2-6)]
Total Total of all reporting groups

Baseline Measures
    Cohort 1     Cohort 2     Cohort 2a     Cohort 2b     Cohort 6     Cohort 7     Total  
Number of Participants  
[units: participants]
 		  3     5     3     3     5     4     23  
Age, Customized  
[units: participants]
 		             
26-35 years of age     0     0     1     0     1     0     2  
36-45 years of age     1     1     0     0     0     0     2  
46-55 years of age     0     0     1     1     1     1     4  
56-65 years of age     1     1     1     2     3     1     9  
66-75 years of age     1     1     0     0     0     2     4  
Over 75 years of age     0     2     0     0     0     0     2  
Gender  
[units: participants]
 		             
Female     2     1     0     2     2     2     9  
Male     1     4     3     1     3     2     14  
Race/Ethnicity  
[units: participants]
 		             
Turkish     0     0     0     1     0     0     1  
White     3     5     3     2     5     4     22  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Maximum Tolerated Dose (MTD) as Determined by the Number of Participants With Dose Limiting Toxicities   [ Time Frame: Day 1 to day 28 ]
  Show Outcome Measure 1

2.  Secondary:   Number of Participants Who Responded to Treatment   [ Time Frame: Every 28 days for up to 6 Months of Treatment ]
  Show Outcome Measure 2


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Study was discontinued due to low enrollment  


Results Point of Contact:  
Name/Title: Executive Vice President, Clinical and Quantitative Sciences
Organization: Merck Sharp & Dohme Corp
phone: 1-800-672-6372


No publications provided


Responsible Party: Executive Vice President, Clinical and Quantitative Sciences, Merck Sharp & Dohme Corp
ClinicalTrials.gov Identifier: NCT00127101     History of Changes
Other Study ID Numbers: 2005_019, MK0683-016
Study First Received: August 2, 2005
Results First Received: July 6, 2009
Last Updated: April 7, 2010
Health Authority: United States: Food and Drug Administration